A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Ruxolitinib (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Aug 2017 Planned primary completion date changed from 1 Sep 2020 to 30 Sep 2020.
- 25 Oct 2016 Planned number of patients changed from 158 to 162.
- 25 Oct 2016 Status changed from not yet recruiting to recruiting.